MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

Core Insights - MAIA Biotechnology is advancing its clinical trials for ateganosine, a novel telomere-targeting agent for non-small cell lung cancer (NSCLC), with 12 patients currently enrolled in the Phase 2 THIO-101 expansion trial [2][3][4] - The FDA has granted Fast Track designation for ateganosine, indicating potential for expedited approval based on promising early results [2][4] - The company is also initiating patient screening for the Phase 3 THIO-104 trial, which aims to evaluate ateganosine in a population with significant unmet medical needs [4][8] Clinical Trials Overview - The Phase 2 THIO-101 trial is designed to assess the safety and efficacy of ateganosine followed by the checkpoint inhibitor cemiplimab in advanced NSCLC patients resistant to prior treatments [8] - The trial has shown promising results, with a patient demonstrating a survival of 30 months, significantly exceeding the current overall survival of approximately 6 months for similar patient populations [4][8] - The Phase 3 THIO-104 trial will compare ateganosine with standard chemotherapy in third-line NSCLC patients resistant to previous therapies [6][8] Market Potential - Ateganoisne has the potential to enhance existing treatment strategies and improve outcomes for advanced NSCLC patients, addressing a critical gap in current cancer therapies [5][9] - The ongoing trials and positive early results position MAIA Biotechnology to potentially capture a significant share of the NSCLC treatment market, particularly for patients with telomerase-positive cancer cells [9]